• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ADMA Biologics Inc

    10/17/24 9:22:50 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADMA alert in real time by email
    SC 13G 1 ADMA_Biologics_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    ADMA BIOLOGICS INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    000899104

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    000899104 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    12,203,756

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    13,004,993

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    13,004,993.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.6%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    000899104 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      ADMA BIOLOGICS INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      465 ROUTE 17 SOUTH RAMSEY NJ 07446 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      000899104

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    000899104 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 13,004,993.00  
      (b) Percent of class: 5.6%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 12,203,756
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 13,004,993
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ¨
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    000899104 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $ADMA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMA

    DatePrice TargetRatingAnalyst
    7/19/2023$5.00Strong Buy
    Raymond James
    10/13/2022$5.00Buy
    Mizuho
    11/11/2021$5.00Outperform → Strong Buy
    Raymond James
    11/9/2021$4.50Overweight
    Cantor Fitzgerald
    10/26/2021$6.00 → $5.00Outperform
    Raymond James
    8/12/2021$7.00 → $6.00Buy
    HC Wainwright & Co.
    7/6/2021$10.00 → $7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ADMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update

    2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted EBITDA(1) of $50.8 Million, a 59% YoY Increase Excluding a Prior-Year Non-Recurring Item 2Q 2025 Adjusted Net Income(2) of $36.0 Million, an 85% YoY Increase Excluding a Prior-Year Non-Recurring Item Initiated Commercial-Scale Manufacturing with FDA-Approved Yield Enhancement Process; Initial Batches Delivering 20%+ Increase in Finished IG Output Secured $300 Million Syndicated Debt Refinancing Led by J.P. Morgan, Consisting of a $75 Million Term Loan Drawn at Closing to Replace Existi

    8/6/25 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025

    RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report second quarter 2025 financial results on August 6, 2025, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and

    7/30/25 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

    1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income(3) of $33.3 Million, an 87% YoY Increase 1Q 2025 Total Cash and Receivables Grew to Approximately $171 Million FDA Approved Yield Enhancement Process Anticipated to Provide 20% Production Output Enhancement from Same Starting Plasma Volume, and Support Revenue Growth and Margin Expansion Opportunity FY 2025 and 2026 Total Revenue Guidance Increased to More than $500 Million and $625 Million, Respectively FY 2025 Adjusted Net In

    5/7/25 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Grossman Adam S exercised 15,000 shares at a strike of $5.40 and sold $354,480 worth of shares (21,000 units at $16.88), decreasing direct ownership by 0.29% to 2,031,850 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    8/15/25 9:00:22 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    COO and SVP, Compliance Kestenberg-Messina Kaitlin M. exercised 2,500 shares at a strike of $8.98 and covered exercise/tax liability with 1,208 shares, increasing direct ownership by 0.27% to 488,690 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    8/1/25 9:00:21 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    COO and SVP, Compliance Kestenberg-Messina Kaitlin M. covered exercise/tax liability with 3,027 shares, decreasing direct ownership by 0.62% to 487,398 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    7/28/25 9:02:55 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    SEC Filings

    View All

    $ADMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form SCHEDULE 13G filed by ADMA Biologics Inc

    SCHEDULE 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

    8/11/25 6:41:13 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by ADMA Biologics Inc

    10-Q - ADMA BIOLOGICS, INC. (0001368514) (Filer)

    8/6/25 5:15:58 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)

    8/6/25 4:11:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on ADMA Biologics with a new price target

    Raymond James resumed coverage of ADMA Biologics with a rating of Strong Buy and set a new price target of $5.00

    7/19/23 9:02:26 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on ADMA Biologics with a new price target

    Mizuho initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $5.00

    10/13/22 7:18:25 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics upgraded by Raymond James with a new price target

    Raymond James upgraded ADMA Biologics from Outperform to Strong Buy and set a new price target of $5.00

    11/11/21 6:21:44 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Financials

    Live finance-specific insights

    View All

    ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update

    2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted EBITDA(1) of $50.8 Million, a 59% YoY Increase Excluding a Prior-Year Non-Recurring Item 2Q 2025 Adjusted Net Income(2) of $36.0 Million, an 85% YoY Increase Excluding a Prior-Year Non-Recurring Item Initiated Commercial-Scale Manufacturing with FDA-Approved Yield Enhancement Process; Initial Batches Delivering 20%+ Increase in Finished IG Output Secured $300 Million Syndicated Debt Refinancing Led by J.P. Morgan, Consisting of a $75 Million Term Loan Drawn at Closing to Replace Existi

    8/6/25 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025

    RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report second quarter 2025 financial results on August 6, 2025, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and

    7/30/25 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

    1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income(3) of $33.3 Million, an 87% YoY Increase 1Q 2025 Total Cash and Receivables Grew to Approximately $171 Million FDA Approved Yield Enhancement Process Anticipated to Provide 20% Production Output Enhancement from Same Starting Plasma Volume, and Support Revenue Growth and Margin Expansion Opportunity FY 2025 and 2026 Total Revenue Guidance Increased to More than $500 Million and $625 Million, Respectively FY 2025 Adjusted Net In

    5/7/25 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ADMA Biologics Inc

    SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)

    11/12/24 1:34:17 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by ADMA Biologics Inc

    SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

    11/8/24 9:21:37 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by ADMA Biologics Inc

    SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

    11/4/24 11:00:41 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Leadership Updates

    Live Leadership Updates

    View All

    ADMA Biologics Set to Join S&P SmallCap 600 Index

    RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. "ADMA's inclusion in the S&P SmallCap 600 index is a significant milestone for our company," Adam Grossman, President and Chief Executive Officer of ADMA. "We expect this inclusion will increase our visibility within the investment communit

    9/17/24 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon is a highly accomplished corporate executive in the life sciences and biotechnology space. He brings over a decade of expertise in strategic advising, corporate finance and business development transactions to ADMA's Board. "Young is a recognized leader in the healthcare sector and his deep strategic and financial experience

    10/18/21 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care